3 results
The primary objective of this study is to test the hypothesis that evacetrapib 130 mg daily, in comparison to placebo, reduces the incidence of the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke, coronary…
Primary Objectives- To replicate AVP-induced inhibition of anterior cingulate cortex (ACC) activity and functional connectivity as measured by BOLD fMRI during a face matching task. - To assess the effect of RO5285119 in the modulation of AVP…
This is a placebo- and active-controlled dose-range-finding study which isalso designed to assess the efficacy and safety of preladenant 2, 5, 10 mg twicedaily versus placebo as an adjunct therapy to L-dopa when administered to subjectswith moderate…